RU2015128766A - Нереплицируемые происходящие от вирусов частицы и их применение - Google Patents
Нереплицируемые происходящие от вирусов частицы и их применение Download PDFInfo
- Publication number
- RU2015128766A RU2015128766A RU2015128766A RU2015128766A RU2015128766A RU 2015128766 A RU2015128766 A RU 2015128766A RU 2015128766 A RU2015128766 A RU 2015128766A RU 2015128766 A RU2015128766 A RU 2015128766A RU 2015128766 A RU2015128766 A RU 2015128766A
- Authority
- RU
- Russia
- Prior art keywords
- rna
- rhabdovirus
- product
- derived
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
- C12N2760/20263—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Claims (18)
1. Продукт для воздействия на злокачественные клетки у субъекта, содержащий нереплицируемую, проникающую в клетки происходящую от Rhabdovirus частицу, причем указанная происходящая от Rhabdovirus частица содержит РНК, которую сшивают или расщепляют на по меньшей мере две прерывистые последовательности полинуклеотида РНК.
2. Продукт по п. 1, в котором указанная происходящая от Rhabdovirus частица содержит:
РНК, сшитую с другими нуклеотидами РНК, с аминокислотами в структуре белка вокруг РНК Rhabdovirus или
структуру белка вокруг РНК, сшитую с другим белком белковой структуры или другой аминокислотой того же самого белка,
или и то и другое.
3. Продукт по п. 1, причем указанная РНК содержит по меньшей мере 0,05% сшитых нуклеотидов.
4. Продукт по п. 1, в котором указанная нереплицируемая, проникающая в клетки происходящая от Rhabdovirus частица содержит по меньшей мере 60 белков G на одну частицу.
5. Продукт по п. 1 для воздействия на злокачественные клетки, причем указанный продукт применяется в комбинации со вторым фармакологическим средством.
6. Продукт по п. 1, полученный способом подвергания живого Rhabdovirus действию повреждающего РНК средства в условиях для сшивания РНК Rhabdovirus, расщепления структуры РНК Rhabdovirus или и того и другого.
7. Способ лечения злокачественной опухоли у субъекта, предусматривающий введение продукта по п. 1 нуждающемуся в этом субъекту.
8. Способ по п. 7, при котором от приблизительно 1×1010 до приблизительно 1×1015 происходящих от Rhabdovirus частиц вводят субъекту.
9. Способ по п. 7, дополнительно предусматривающий введение второго фармацевтического средства субъекту.
10. Способ по п. 9, при котором фармацевтическое средство представляет собой химиотерапевтическое средство.
11. Способ получения продукта, как определено в п. 1, включающий стадию:
подвергания живого Rhabdovirus действию повреждающего РНК средства в условиях для сшивания РНК Rhabdovirus, расщепления структуры РНК Rhabdovirus или и того и другого для производства нереплицируемых, проникающих в клетки происходящих от Rhabdovirus частиц.
12. Способ по п. 11, при котором повреждающее РНК средство представляет собой электромагнитное излучение, химическое сшивающее средство или и то и другое.
13. Способ по п. 11, при котором электромагнитное излучение характеризуется длиной волны менее чем приблизительно 1 мм.
14. Способ по п. 12, при котором повреждающее РНК средство представляет собой электромагнитное излучение в дозе от приблизительно 100 мДж/см2 до приблизительно 8000 мДж/см2 или гамма-облучение в дозе от 1 кГр до приблизительно 50 кГр.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740856P | 2012-12-21 | 2012-12-21 | |
| US61/740,856 | 2012-12-21 | ||
| US201361835310P | 2013-06-14 | 2013-06-14 | |
| US61/835,310 | 2013-06-14 | ||
| PCT/CA2013/051009 WO2014094182A1 (en) | 2012-12-21 | 2013-12-20 | Non-replicating virus-derived particles and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015128766A true RU2015128766A (ru) | 2017-01-26 |
| RU2705556C2 RU2705556C2 (ru) | 2019-11-07 |
Family
ID=50977496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015128766A RU2705556C2 (ru) | 2012-12-21 | 2013-12-20 | Нереплицируемые происходящие от вирусов частицы и их применение |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11110138B2 (ru) |
| EP (1) | EP2935569B1 (ru) |
| JP (2) | JP6612619B2 (ru) |
| KR (1) | KR102167497B1 (ru) |
| CN (1) | CN105121636A (ru) |
| AU (1) | AU2013362761B2 (ru) |
| BR (1) | BR112015015045A8 (ru) |
| CA (1) | CA2896162C (ru) |
| CL (1) | CL2015001738A1 (ru) |
| ES (1) | ES2745599T3 (ru) |
| HK (1) | HK1210624A1 (ru) |
| IL (1) | IL239486B (ru) |
| MX (1) | MX2015008155A (ru) |
| MY (1) | MY174912A (ru) |
| PH (1) | PH12015501442A1 (ru) |
| RU (1) | RU2705556C2 (ru) |
| SG (2) | SG10201704903YA (ru) |
| WO (1) | WO2014094182A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2935569B1 (en) * | 2012-12-21 | 2019-05-01 | Celverum Inc. | Non-replicating rhabdovirus-derived particles and uses thereof |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| CN109985244A (zh) * | 2017-12-29 | 2019-07-09 | 广州威溶特医药科技有限公司 | E3连接酶抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
| CN109432098B (zh) * | 2018-11-20 | 2021-04-13 | 天津大学 | 化合物ps-341在制备小rna病毒科肠道病毒属病毒抑制剂的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106619A (en) | 1983-12-20 | 1992-04-21 | Diamond Scientific Co. | Preparation of inactivated viral vaccines |
| JP5208343B2 (ja) * | 2000-06-26 | 2013-06-12 | ウェルスタット バイオロジクス コーポレイション | ウイルスを用いる細胞の浄化 |
| CN1820078A (zh) * | 2002-09-09 | 2006-08-16 | 田纳西大学研究基金会 | 弹状病毒的重组突变体及其应用方法 |
| CN100579579C (zh) * | 2002-10-01 | 2010-01-13 | 诺华疫苗和诊断公司 | 抗癌及抗感染性疾病组合物及其使用方法 |
| JP4708027B2 (ja) * | 2002-10-01 | 2011-06-22 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法 |
| CA2500661A1 (en) * | 2002-10-01 | 2004-04-15 | Chiron Corporation | Anti-cancer and anti-infectious disease compositions and methods for using same |
| EP1606411B1 (en) * | 2003-03-27 | 2008-12-10 | Ottawa Health Research Institute | Mutant vesicular stomatitis viruses and use thereof |
| US7807176B2 (en) * | 2004-03-19 | 2010-10-05 | Genomidea, Inc. | Polypeptide promoting vascular endothelial cell growth |
| US8703467B2 (en) * | 2004-05-27 | 2014-04-22 | Baxter International Inc. | Inactivation of a pathogen in a sample by a treatment with formalin and UV light |
| CA2921048C (en) * | 2006-09-15 | 2018-06-05 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| ES2532808T3 (es) | 2008-09-16 | 2015-03-31 | Genomidea Inc. | Agente terapéutico/profiláctico para cáncer de próstata |
| MX337062B (es) * | 2009-12-10 | 2016-02-11 | Ottawa Hospital Res Inst | Rabdovirus oncolítico. |
| WO2012103510A2 (en) * | 2011-01-27 | 2012-08-02 | Lentigen Cororation | Advanced prime and boost vacinne |
| EP2671109A2 (en) * | 2011-02-02 | 2013-12-11 | Corning Cable Systems LLC | Dense fiber optic connector assemblies and related connectors and cables suitable for establishing optical connections for optical backplanes in equipment racks |
| WO2012122649A1 (en) * | 2011-03-15 | 2012-09-20 | Ottawa Hospital Research Institute | Recombinant orf virus |
| US9623096B2 (en) * | 2011-11-09 | 2017-04-18 | Celverum Inc. | Virally infected hematopoietic cells and uses thereof |
| EP2935569B1 (en) * | 2012-12-21 | 2019-05-01 | Celverum Inc. | Non-replicating rhabdovirus-derived particles and uses thereof |
-
2013
- 2013-12-20 EP EP13865170.8A patent/EP2935569B1/en active Active
- 2013-12-20 MY MYPI2015702052A patent/MY174912A/en unknown
- 2013-12-20 KR KR1020157019923A patent/KR102167497B1/ko active IP Right Grant
- 2013-12-20 SG SG10201704903YA patent/SG10201704903YA/en unknown
- 2013-12-20 AU AU2013362761A patent/AU2013362761B2/en not_active Ceased
- 2013-12-20 MX MX2015008155A patent/MX2015008155A/es active IP Right Grant
- 2013-12-20 ES ES13865170T patent/ES2745599T3/es active Active
- 2013-12-20 BR BR112015015045A patent/BR112015015045A8/pt not_active Application Discontinuation
- 2013-12-20 SG SG11201504843UA patent/SG11201504843UA/en unknown
- 2013-12-20 RU RU2015128766A patent/RU2705556C2/ru active
- 2013-12-20 CA CA2896162A patent/CA2896162C/en not_active Expired - Fee Related
- 2013-12-20 JP JP2015548131A patent/JP6612619B2/ja not_active Expired - Fee Related
- 2013-12-20 WO PCT/CA2013/051009 patent/WO2014094182A1/en active Application Filing
- 2013-12-20 CN CN201380071341.1A patent/CN105121636A/zh active Pending
- 2013-12-20 US US14/654,259 patent/US11110138B2/en active Active
-
2015
- 2015-06-17 IL IL239486A patent/IL239486B/en active IP Right Grant
- 2015-06-18 CL CL2015001738A patent/CL2015001738A1/es unknown
- 2015-06-19 PH PH12015501442A patent/PH12015501442A1/en unknown
- 2015-11-18 HK HK15111350.4A patent/HK1210624A1/xx unknown
-
2019
- 2019-09-11 JP JP2019165067A patent/JP2020014467A/ja active Pending
-
2021
- 2021-07-21 US US17/382,146 patent/US20210346441A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2935569A4 (en) | 2016-08-03 |
| ES2745599T3 (es) | 2020-03-02 |
| MX2015008155A (es) | 2016-02-05 |
| KR20150112957A (ko) | 2015-10-07 |
| SG10201704903YA (en) | 2017-07-28 |
| IL239486A0 (en) | 2015-07-30 |
| BR112015015045A8 (pt) | 2018-01-23 |
| EP2935569A1 (en) | 2015-10-28 |
| WO2014094182A1 (en) | 2014-06-26 |
| AU2013362761B2 (en) | 2019-08-01 |
| US20150320810A1 (en) | 2015-11-12 |
| CA2896162C (en) | 2021-10-12 |
| EP2935569B1 (en) | 2019-05-01 |
| NZ709439A (en) | 2020-09-25 |
| KR102167497B1 (ko) | 2020-10-20 |
| CA2896162A1 (en) | 2014-06-26 |
| IL239486B (en) | 2019-08-29 |
| CN105121636A (zh) | 2015-12-02 |
| PH12015501442A1 (en) | 2015-09-14 |
| AU2013362761A1 (en) | 2015-07-16 |
| JP6612619B2 (ja) | 2019-11-27 |
| JP2020014467A (ja) | 2020-01-30 |
| MY174912A (en) | 2020-05-21 |
| SG11201504843UA (en) | 2015-07-30 |
| HK1210624A1 (en) | 2016-04-29 |
| US20210346441A1 (en) | 2021-11-11 |
| CL2015001738A1 (es) | 2015-12-18 |
| JP2016501538A (ja) | 2016-01-21 |
| RU2705556C2 (ru) | 2019-11-07 |
| US11110138B2 (en) | 2021-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200062T1 (hr) | Postupak proučavanja nukleinskih kiselina | |
| RU2015128766A (ru) | Нереплицируемые происходящие от вирусов частицы и их применение | |
| Stimpfel et al. | New challenge: mitochondrial epigenetics? | |
| JP2013523181A5 (ru) | ||
| BR112012029588A2 (pt) | materiais biológicas relacionados a her3. | |
| JP2015145500A5 (ru) | ||
| EA201400401A1 (ru) | Биокомпозит для регенерации поврежденных тканей и органов, набор для изготовления биокомпозита и способ лечения | |
| MX367842B (es) | Método compartimentado de administración de ácidos nucleicos y composiciones y usos del mismo. | |
| MX364396B (es) | Poli(beta-amino esteres) modificados para suministro de farmaco. | |
| AR120138A1 (es) | Proteínas de fijación multiespecíficas para tratamiento contra el cáncer | |
| BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
| EA201401281A1 (ru) | D-аминокислотные химические соединения для лечения заболеваний печени | |
| EA201200515A1 (ru) | Полипептиды и их применение | |
| BR112022008744A2 (pt) | Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico | |
| JP2016501013A5 (ru) | ||
| RU2015102027A (ru) | Проникающие в клетку пептиды и способы идентификации проникающих в клетку пептидов | |
| Wu et al. | Light-responsive charge-reversal nanovector for high-efficiency in vivo CRISPR/Cas9 gene editing with controllable location and time | |
| EA201501099A3 (ru) | Способ получения катионных амфифильных блок-сополимеров n, n-диметиламиноэтилметакрилата для доставки нуклеиновых кислот в живые клетки | |
| EA201790178A1 (ru) | Пептиды, несущие маннозо-6-фосфат, слитые с лизосомальным ферментом | |
| CN108853515B (zh) | 短肽水凝胶的制备方法及应用、药物组合物 | |
| KR101112756B1 (ko) | 광반응성 키토산 유도체 및 그의 용도 | |
| JP2016501538A5 (ru) | ||
| CN103596594A (zh) | 自身凝胶化核酸 | |
| CN110368398A (zh) | 基于沸石咪唑骨架的递送microRNA纳米载体及制备方法 | |
| RU2017121091A (ru) | Композиции и способы для модуляции активности ат2r |